Lewes, DE -- (SBWIRE) -- 08/30/2013 -- LeadingStockAlerts is a financial marketing firm that specializes in assisting the underserved small cap and micro-cap stock community. Out Today’s Focus is on: AMR Corporation(OTCMKTS:AAMRQ), Medical Marijuana Inc(OTCMKTS:MJNA), Invivo Therapeutics Holdings Corp(OTCBB:NVIV), Affymax, Inc.(OTCMKTS:AFFY).
AMR Corporation(OTCMKTS:AAMRQ) ended higher +11.15% and complete the day at $3.39. The total number of shares changed hands during the day was 17.12 million. After opening at $3.19, the stock hit as high as $3.39. However, it traded between $0.36 and $7.15 over the last twelve months.
AMR Corporation (AMR) operates in the airline industry. The Company’s principal subsidiary is American Airlines, Inc. (American). As of December 31, 2011, American provided scheduled jet service to approximately 160 destinations throughout North America,
For How Long AAMRQ will Fight for Profitability? Read This Trend Analysis report
Medical Marijuana Inc(OTCMKTS:MJNA) closed yesterday at $0.195, a +49.92% increase. Around 49.61 million shares were traded, beating an-average trading volume of 7.89 million shares. The company is now valued at around $182.42 million.
Medical Marijuana Inc. (MJNA) is the publicly held company vested in the medical marijuana and industrial hemp markets. It is comprised of a diversified portfolio of products, services, technology and businesses solely focused on the cannabis and hemp industries.
For How Long MJNA Gloss will Attract Investors? Find out via this report
Invivo Therapeutics Holdings Corp(OTCBB:NVIV) moved -14.04 percent lower at $1.47 and traded between $1.31 and $1.82 after opening the day at $1.65. Its performance over the last five days remained -64.98%, which stands at -71.4% for a month. Going back further than one month, 1-year performance after recent close was -15.52%.
InVivo Therapeutics Holdings Corp., formerly Design Source, Inc. is a development-stage company. The Company is developing and commercializing technologies for the treatment of spinal cord injuries. The Company develops biopolymer scaffolding devices for the treatment of spinal cord injuries.
Why Should Investors Buy NVIV After the Recent Fall? Just Go Here and Find Out
Affymax, Inc.(OTCMKTS:AFFY) shares rose, gaining 9.06 percent to close at $1.71. The stock is down around -91% this year and -90.01% for the last 12 months. Around 2.68 million shares changed hands yesterday, higher from an-average trading volume of 1.38 million shares.
Affymax, Inc. is a biopharmaceutical company engaged in developing drugs to improve the treatment of serious and often life-threatening conditions. Its product candidate, peginesatide, is for the treatment of anemia in chronic kidney disease patients on dialysis. Peginesatide is a synthetic peptide-based erythropoiesis stimulating agent (ESA), designed to stimulate production of red blood cells.
Why Should Investors Buy AFFY After The Recent Gain? Just Go Here and Find Out
LeadingStockAlerts is a financial marketing firm that specializes in assisting the underserved small cap and micro-cap stock community.
Our site has been the clear choice for today’s investors and day-traders. As one of the internet’s premiere financial destinations, we offer the investment community some of the market’s leading emerging opportunities. Using a balanced combination of industry experience and high-tech offerings, this site keeps you ahead of the curve and ahead of the bell.
DO NOT BASE ANY INVESTMENT DECISION UPON ANY MATERIALS FOUND ON THIS REPORT OR WEBSITE. We are not registered as a securities broker-dealer or an investment adviser either with the U.S. Securities and Exchange Commission (the “SEC”) or with any state securities regulatory authority. We are neither licensed nor qualified to provide investment advice.
The information contained in our report should be viewed as commercial advertisement and is not intended to be investment advice. The report is not provided to any particular individual with a view toward their individual circumstances. The information contained in our report is not an offer to buy or sell securities. We distribute opinions, comments and information free of charge exclusively to individuals who wish to receive them.
Read Full Disclaimer at: http://leadingstockalerts.com/disclaimer/
Copyright © 2005-2013 - SBWire, The Small Business Newswire - All Rights Reserved - Important Disclaimer
Contact Us: 888-4-SBWIRE (US) - 920-593-5640 (International)